NovoCure Limited
NVCR
$12.43
$0.524.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.46% | -3.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.46% | -3.89% | |||
| Cost of Revenue | 7.66% | 18.48% | |||
| Gross Profit | 0.74% | -9.54% | |||
| SG&A Expenses | 0.46% | -28.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.83% | -13.75% | |||
| Operating Income | -4.37% | 39.27% | |||
| Income Before Tax | -15.46% | 45.12% | |||
| Income Tax Expenses | 28.23% | -62.45% | |||
| Earnings from Continuing Operations | -16.96% | 47.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.96% | 47.94% | |||
| EBIT | -4.37% | 39.27% | |||
| EBITDA | -4.45% | 43.02% | |||
| EPS Basic | -15.62% | 48.79% | |||
| Normalized Basic EPS | -14.09% | 63.38% | |||
| EPS Diluted | -15.62% | 48.80% | |||
| Normalized Diluted EPS | -14.09% | 63.38% | |||
| Average Basic Shares Outstanding | 1.17% | 1.67% | |||
| Average Diluted Shares Outstanding | 1.17% | 1.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||